News
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Telomir-1, a small molecule by Telomir Pharmaceuticals, shows promising results in promoting life quality and longevity in senior dogs. The pre-clinical-stage company's research aims to lead developments in longevity science through the treatment of age-related conditions -
COMMUNIQUÉ DE PRESSE
Lukoil, Rosneft, Tatneft: Avoid Total Loss – Immediate Action Required to Convert ADRs to Shares by October 1, 2024
Investors advised to convert Lukoil, Rosneft, Tatneft ADRs to shares by Oct 1, 2024 due to OFAC License 100A & EU support. Immediate action needed for dividend claims. Weisswert offers support -
COMMUNIQUÉ DE PRESSE
Original-Research: LAIQON AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on LAIQON AG with a Buy rating and EUR 9.80 price target. LAIQON is an independent wealth and asset management firm with innovative Digital Asset Platform (DAP) 4.0 focusing on ESG investment solutions -
-
COMMUNIQUÉ DE PRESSE
Signal Gold Intersects Further High-Grade Gold at the Western Extension of Goldboro, Including 17.97 Gold Over 2.5 Metres and 19.00 g/t Over 2.4 Metres
Signal Gold Inc. reports high-grade gold results from drilling program at Goldboro Project in Nova Scotia, aiming to expand open-pit resources -
-
COMMUNIQUÉ DE PRESSE
Diversified Energy Announces Joint Acquisition to Acquire Package of High-Quality East Texas Assets
Diversified Energy Company PLC announces acquisition of natural gas properties in East Texas, expanding footprint and increasing scale in the region. Acquisition highlights Proved Developed Producing (PDP) assets and undeveloped acreage -
COMMUNIQUÉ DE PRESSE
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
Destiny Pharma to deliver presentation on XF-73 Nasal Gel at ESCMID conference highlighting rapid reduction in S. aureus nasal burden and lower need for post-operative antibiotics -
